<DOC>
	<DOCNO>NCT00451035</DOCNO>
	<brief_summary>This study evaluate efficacy safety LBH589B adult patient chronic phase chronic myeloid leukemia resistant disease follow treatment least two BCR-ABL tyrosine kinase inhibitor</brief_summary>
	<brief_title>Efficacy Safety LBH589 Adult Patients With Refractory Chronic Myeloid Leukemia ( CML ) Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : Male female patient age ≥ 18 year old Diagnosis Philadelphia chromosome positive , chronic phase chronic myeloid leukemia Prior treatment least two BCRABL tyrosine kinase inhibitor demonstrate resistance recent kinase inhibitor therapy . Patients history intolerance one BCRABL kinase inhibitor consider eligible enter study demonstrate resistance recent BCRABL kinase inhibitor . Patients intolerant least 2 BCRABL kinase inhibitor consider eligible enter study also demonstrate resistance intolerance interferonalpha ( IFNα ) criterion define . Patients must adequate laboratory value Baseline measurement leave ventricular ejection fraction [ assessment heart ability pump effectively ] Assessment patient ability perform every day activity . Assessment ECOG [ Eastern Cooperative Oncology Group ] Performance Status Exclusion criterion : A candidate hematopoietic stem cell transplantation Prior therapy certain medication Patients prior history accelerate phase blast crisis CML Impaired cardiac function clinically significant cardiac disease Concomitant use certain medication Impairment GI function GI disease Patients unresolved diarrhea Patients receive chemotherapy , investigational drug undergone major surgery &lt; 4 week prior start study drug recover side effect therapy Patients receive BCRABL tyrosinekinase inhibitor within 1 week first treatment LBH589 Women pregnant breast feed woman childbearing potential use effective method birth control Male patient whose sexual partner woman child bear potential use effective birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Refractory Chronic Myeloid Leukemia Chronic Phase</keyword>
	<keyword>adult</keyword>
	<keyword>oral LBH589</keyword>
</DOC>